sirpiglenastat

N/A

Report date: 2025/12/18 20:00:07
NME

Base Information

Drug Namesirpiglenastat
Drug Alias NameDRP-104
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamine-utilizing Enzyme inhibitors
TargetsGlutamine-utilizing Enzyme
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins UniversityInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesNyu Langone Health
Inactive CompaniesDracen Pharmaceuticals Inc
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A